) recently provided additional data on its diagnostic imaging
agent etarfolatide (EC20) which is being evaluated for use in
patients with ovarian cancer and non-small cell lung cancer
Results showed that etarfolatide helps identify patients with
ovarian cancer and NSCLC who are more likely to benefit from
folate receptor-targeted therapeutics like vintafolide
Endocyte said that patients with all target tumor lesions
positive as assessed by etarfolatide, FR (100%) showed
substantial progression-free survival on vintafolide compared to
patients with 10 to 90% of target lesions positive for folate
receptor, FR (10-90%).
According to information provided by Endocyte, ovarian cancer is
estimated to affect 22,280 new patients in the US and more than
40,000 new patients in the EU.
Vintafolide is currently being evaluated in the phase III PROCEED
trial (in women with platinum resistant ovarian cancer) and the
phase IIb TARGET trial in NSCLC patients.
Endocyte and its partner,
Merck & Co. Inc.
), are looking to get vintafolide approved as a treatment for
patients suffering from folate-receptor positive
platinum-resistant ovarian cancer in combination with pegylated
liposomal doxorubicin (PLD). The companies entered into a
partnership in Apr 2012.
Under this agreement, Endocyte granted Merck an exclusive
license to develop, manufacture and commercialize the
Endocyte is seeking EU approval for etarfolatide along with
vintafolide. Both candidates were granted orphan drug status in
the EU in 2012. The company expects a decision from the European
Commission on both candidates towards the end of 2013.
We expect investor focus to remain on the regulatory status of
vintafolide and etarfolatide.
Endocyte carries a Zacks Rank #3 (Hold). Currently, companies
Lannett Company, Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
ENDOCYTE INC (ECYT): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis
QLT INC (QLTI): Free Stock Analysis Report
To read this article on Zacks.com click here.